Insider Transactions in Q3 2024 at Mereo Biopharma Group PLC (MREO)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
60,046
-6.91%
|
$240,184
$4.22 P/Share
|
|
Sep 13
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
100,312
-36.64%
|
$401,248
$4.22 P/Share
|
|
Sep 13
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,158
-17.67%
|
$76,632
$4.22 P/Share
|
|
Sep 13
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
20,946
-8.73%
|
$83,784
$4.22 P/Share
|
|
Sep 13
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,937
-12.21%
|
$43,748
$4.22 P/Share
|
|
Sep 12
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,611
-3.19%
|
$114,444
$4.47 P/Share
|
|
Sep 12
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
47,798
-12.45%
|
$191,192
$4.47 P/Share
|
|
Sep 12
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,128
-7.76%
|
$36,512
$4.47 P/Share
|
|
Sep 12
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
9,980
-3.99%
|
$39,920
$4.47 P/Share
|
|
Sep 12
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,212
-5.5%
|
$20,848
$4.47 P/Share
|
|
Sep 11
2024
|
Charles Sermon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
65,600
+20.79%
|
-
|
|
Sep 11
2024
|
Christine Ann Fox Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+33.79%
|
-
|
|
Sep 11
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
208,333
+31.41%
|
$0
$0.8 P/Share
|
|
Sep 11
2024
|
Denise Scots Knight Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
188,060
+17.32%
|
-
|
|
Sep 11
2024
|
John A. Lewicki Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,000
+32.68%
|
-
|
|
Aug 22
2024
|
Deepika Pakianathan |
SELL
Open market or private sale
|
Direct |
105,244
-100.0%
|
$420,976
$4.43 P/Share
|
|
Aug 22
2024
|
Deepika Pakianathan |
BUY
Exercise of conversion of derivative security
|
Direct |
105,244
+33.73%
|
$210,488
$2.28 P/Share
|